KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Non-Current Deferred Tax Liability: 2022-2024

Historic Non-Current Deferred Tax Liability for Recursion Pharmaceuticals (RXRX) over the last 3 years, with Dec 2024 value amounting to $16.6 million.

  • Recursion Pharmaceuticals' Non-Current Deferred Tax Liability rose 13776.19% to $23.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $23.3 million, marking a year-over-year increase of 13776.19%. This contributed to the annual value of $16.6 million for FY2024, which is 2.03% down from last year.
  • According to the latest figures from FY2024, Recursion Pharmaceuticals' Non-Current Deferred Tax Liability is $16.6 million, which was down 2.03% from $16.9 million recorded in FY2023.
  • In the past 5 years, Recursion Pharmaceuticals' Non-Current Deferred Tax Liability registered a high of $16.9 million during FY2023, and its lowest value of $11.9 million during FY2022.
  • Its 3-year average for Non-Current Deferred Tax Liability is $15.1 million, with a median of $16.6 million in 2024.
  • Its Non-Current Deferred Tax Liability has fluctuated over the past 5 years, first skyrocketed by 41.77% in 2023, then fell by 2.03% in 2024.
  • Recursion Pharmaceuticals' Non-Current Deferred Tax Liability (Yearly) stood at $11.9 million in 2022, then skyrocketed by 41.77% to $16.9 million in 2023, then fell by 2.03% to $16.6 million in 2024.